Thu, Nov 27, 2014, 10:12 PM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

mgm2020 688 posts  |  Last Activity: 11 hours ago Member since: Mar 3, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Has every excuse to give back last weeks gains

    by davecarmen48 Nov 3, 2014 12:44 PM
    mgm2020 mgm2020 Nov 4, 2014 11:01 AM Flag

    Keeping a close eye on KERX. Everyone over there could obviously tell that I am a very emotional investor and trader. The events following the approval definitely triggered an emotional response, which I may very well regret. But I will probably rejoin KERX at some point. For now TROV looks very good as more news and commercialization approach.

    Sentiment: Strong Buy

  • Reply to

    Has every excuse to give back last weeks gains

    by davecarmen48 Nov 3, 2014 12:44 PM
    mgm2020 mgm2020 Nov 3, 2014 9:41 PM Flag

    And every reason to climb back up to $7 with commercialization coming----and it will. Good to see you dave.

    Sentiment: Strong Buy

  • Reply to

    MGM has bailed on KERX...

    by josephanastasiw Nov 3, 2014 6:17 PM
    mgm2020 mgm2020 Nov 3, 2014 9:40 PM Flag

    Joe---I held and traded KERX for nearly 2 years and watched the manipulators abuse the stock following the approval of ferric citrate. All of the calls and posts I made on the KERX board were based on my sentiment, which was always positive. Why do you care what stocks I am investing in? If you follow my posting history you will see that I always post positively regarding the stocks I invest in-----not because I am trying to make the stock go up----that is STUPID-----but because I EXPECT the stocks to go up. If you want to make some money----make that A LOT of money, then you can take a good look at TROV, IDRA, SUNE, and ACAD. You can also go back and see that I was strongly recommending TROV when it was down close to $3----just a few months ago. Now it is over $5 and heading up to $10 or more in the next 6-8 months. I welcome you to come back in 6 months and thank me for introducing you and many others to TROV----but in the meantime----why don't you mind your own business. And by the way-----I made over $200K in KERX and may re-enter if the opportunity presents.

    Sentiment: Strong Buy

  • the 50DMA and the 10 day crosses above that also we have a very strong buy signal. Last time that happned the stock went from $2.50 to $3.50 in 10 days back in June.

    Sentiment: Strong Buy

  • it's possible that the stock may get back to $3 much faster than we think. And once it gets back above $3 it may really start snowballing higher like it did 6 months ago into and beyond the WM data-----an other new news.

    Sentiment: Strong Buy

  • Reply to

    Article on ACAD from yesterday

    by zwerp2000 Oct 23, 2014 8:37 AM
    mgm2020 mgm2020 Oct 23, 2014 8:54 AM Flag

    Excellent article, except the last sentence should read, this is why Pimavanserin WILL offer a viable and much more effective treatment-----but we'll have to wait for approval for that statement, and it won't be long now. And those are the same qualities and pharmacokinetics that will make it an absolute blockbuster not only for PDP, but Alzheimer's psychosis, sleep disorders, and many other neurologic applications.

    Sentiment: Strong Buy

  • should continue. Interesting move on a day when a lot of stocks gave back the gains from the last couple of days. There is a lot of positioning going on with IDRA to get in and BE in when the next news is released, which could be any time-----and I'm not just talking about WM, but any new trials that will be undertaken, new applications, or PARTNERSHIP. ISIS is cleaning up with all of their partnership deals, and with ALL of the applications of 8400, 9200, and anything else currently in the developmental stage the partnership offers could be very lucrative.

    Sentiment: Strong Buy

  • Buying momentum and volume are picking up. 2 bullish signs. Trials to begin on 9200 and WM data coming out soon. The stock has based for way too long and when it breaks out it will be a HUGE move to the upside.

    Sentiment: Strong Buy

  • or take your position up to a higher level before the next explosive move back into the $6's----or higher----to stay. Once the rollout begins the technology will be embraced by oncologists clamoring for an easier method to monitor, quantify, and assess mutation status and load of their patient's cancer and customize treatment accordingly. This is the ONLY non-invasive method of quantifying treatment progress or relapse IN NEAR REAL-TIME that can be easily repeated at any frequency determined by the doctor----AT HOME and without a technician present. Blood tests and imaging eventually will become the secondary testing method as these simple urine tests will be much more cost-effective without sacrificing ANY accuracy----in fact they are MORE PRECISE at detecting mutation load and status. Looking for the stock to be back in the $6's by year end and higher into early 2015 and beyond. I have now rebought back my entire position.

    Sentiment: Strong Buy

  • Reply to

    Einhorn - some good some bad

    by biilooslhi500 Oct 21, 2014 8:07 PM
    mgm2020 mgm2020 Oct 22, 2014 9:02 AM Flag

    Einhorn is just one of the factors behind the (justified) increase in the price of the stock. First Zack's upgraded SUNE to a #1 STRONG BUY, then BOA came out with a PT of $24, and Cowen not only agreed but they increased the PT to $28. So, while you can discount what Einhorn said if you want, you can not disregard ALL of the positive sentiment and views on SUNE in the past week. And contrary to what many people seem to think about the connection between oil prices an solar energy, there is NO connection. Solar is becoming MUCH less expensive to install and will reach parity with traditional power generation in the next few years, PLUS, there is much LESS expense on upkeep, maintenance, and moving parts with solar. The energy source is also INDEFINITE and NEVER requires refueling or repurchasing. The rest of the world is installing and converting to solar much more quickly than we are, and with the likelihood of moving into China SUNE will greatly enhance it's value. Best in breed and growing like crazy-----BUY and hold for 5 years to cash in for at least a TRIPLE from here.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Oct 21, 2014 3:11 PM Flag

    Hey w4k---we all DO know that it's coming, BUT, the wild card here is the breakthrough designation and priority review. I'm pegging this at a minimum of $36 prior to approval, so at least a $10 increase from here.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Oct 21, 2014 2:29 PM Flag

    The feeling is mutual for brainless and pointless replies. You DO know that Cramer spotlighted ACAD and ISIS a few weeks ago as 2 of the most enticing biotech buyout candidates because of their pipeline and prospects?

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Oct 21, 2014 11:57 AM Flag

    I don't think so. And don't believe for a second that this thought is not in EVERYONE'S mind that holds ACAD. What is the purpose of your reply exactly?

    Sentiment: Strong Buy

  • Someone or some fund wants in here. 274K shares at the bid right now. Over half a million worth of IDRA-----that will be worth much more in a few months. The market is turning-----and so will IDRA.

    Sentiment: Strong Buy

  • And that will help propel the stock to new highs when they begin to come to their senses. Upgraded by Zack's to #1 STRONG BUY, Cowen, and Bank of America with an average price target of $26. And THAT is ONLY THE BEGINNING! With a GIGAWATT expansion into China and the lowest production and installation cost in the industry it's just a matter of (a little) time before they take more and more market share. Add another revenue stabilizing and generating yieldco and this stock could double in the next 2 years.

    Sentiment: Strong Buy

  • Reply to

    Question about psoriasis data

    by timehusk Oct 20, 2014 6:34 AM
    mgm2020 mgm2020 Oct 20, 2014 10:15 AM Flag

    According to Jim Baker at IDRA investor relations the company wants to present the data at an appropriate medical conference, but not until it has been totally evaluated, peer-reviewed, and most likely published to coincide with the conference. The bigger question, and the more important question for shareholders is, how could they have decided to escalate the dose of IMO-8400 up to 4 TIMES the .6 dosage for WM without knowing if it was effective or safe? And the answer is----they couldn't! So---I really think the psoriasis data is immaterial as far as a revenue-generating therapeutic is concerned. WM, the myositis, GVH, and ALL of the other autoimmune diseases are where the motherlode is. And we're going to be well on our way towards the end of this year and into and through 2015.

    Sentiment: Strong Buy

  • This will certainly help make the winter go faster. First---NDA. Then 60 day letter of acceptance, breakthrough designation and priority review. Then-----approval by JUNE?? The chances of ACAD being bought increase dramatically following the 60 day letter and with a priority review. What big pharma company wouldn't want to get their hands on Nuplazid and it's myriad of applications. And doctors, patients, and their families who have to deal with the effects of Parkinson's psychosis will be clamoring for this drug. While their will most likely still be some short-lived dips in the stock price prior to the acceptance, this is one stock you do not want to reduce your holdings in, and if possible, pick up more on the dips. $35 minimum by approval and likely higher and any buyout will be in the $50+ range.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Oct 18, 2014 12:42 PM Flag

    When I spoke with him about 2 weeks ago I got the same impression and am extremely optimistic about 2015 as a transitional AND TRANSFORMATIONAL year for IDRA with multiple trials in both platforms underway. The news is starting to flow and the stock will not be presenting this opportunity for long.

    Sentiment: Strong Buy

  • SunEdison shares rally after upgrade
    11:56a ET October 17, 2014 (MarketWatch)

    SunEdison shares rally after upgrade
    By Claudia Assis, MarketWatch
    SAN FRANCISCO (MarketWatch) -- Shares of SunEdison Inc. soared nearly 10% on Friday after analysts at Cowen & Co. upgraded the stock to outperform, saying the solar developer has become even more attractive following the recent selloff in the solar sector.
    SunEdison (SUNE), whose main business is building solar-power plants in the U.S., is a lower risk stock than its peers, and shares should be trading in the low $20s "at a minimum," the Cowen analysts said.
    Cowen has a price target of $24 on SunEdison's stock, which represents 40% upside from Friday's trading.
    The company has "minimal" exposure to Japan, where recently utilities have restricted new solar plants from accessing their grids. It's also a pioneer in the spinoffs known in the industry as "yieldcos", which drive down the cost of its capital, the analysts said.
    SunEdison said last month it plans on a second "yieldco," this time bundling solar projects and assets in emerging markets. That would follow the initial public offering of SunEdison's spinoff TerraForm Power Inc. (TERP) in July.
    At current price levels, the stock "appears to have little baked in its valuation for additional YieldCos or longer term distributions," the Cowen analysts said.

    Sentiment: Strong Buy

  • And looing to BUY here expecting a rise----which IS coming.

    Sentiment: Strong Buy

KERX
15.89+0.06(+0.38%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Infoblox Inc.
NYSEWed, Nov 26, 2014 4:01 PM EST